Stanford University, twoXAR collaborate on liver cancer treatment: 3 notes

The Palo Alto, Calif.-based biopharmaceutical company twoXAR and Stanford University School of Medicine's Asian Liver Center will collaborate to identify liver cancer treatments.

Here's what you need to know:

1. twoXAR develops biomedical software, which evaluates drug candidates through dataset analysis. These evaluations can be used to prioritize drug candidates prior to clinical testing.

2. In this collaboration, twoXAR will use its software to make predictions about drug candidates targeting hepatocellular carcinoma, a form of liver cancer.

3. The drug candidates that twoXAR determines to be high-priority will be put through preclinical studies, conducted by researchers at the Asian Liver Center.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast